Patents Assigned to Genentech
  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF PREVIOUSLY TREATED BREAST CANCER
    Publication number: 20200148756
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, in combination with one or more additional anti-tumor therapeutic agents in previously treated metastatic breast cancer.
    Type: Application
    Filed: September 23, 2019
    Publication date: May 14, 2020
    Applicant: Genentech, Inc.
    Inventors: Rajeshwari Swamy, Julie Hambleton
  • Anti-CLL-1 Antibodies and Methods of Use
    Publication number: 20200148774
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Application
    Filed: October 21, 2019
    Publication date: May 14, 2020
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • METHODS AND COMPOSITION FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES
    Publication number: 20200148783
    Abstract: The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof.
    Type: Application
    Filed: July 18, 2019
    Publication date: May 14, 2020
    Applicant: Genentech, Inc.
    Inventors: Matthew MARRICHI, Dorothea E. REILLY
  • Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
    Patent number: 10646567
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: May 12, 2020
    Assignee: Genentech, Inc.
    Inventors: Heather Maecker, Bryan Irving
  • Compounds and compositions for the inhibition of NAMPT
    Patent number: 10647695
    Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An embodiment of the invention is the provision of a compound of Formula IIIA.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: May 12, 2020
    Assignees: Forma TM, LLC, Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Alexandre J. Buckmelter, Karl H. Clodfelter, Bingsong Han, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng, Po-Wai Yuen
  • Thiazolopyrimidinones and methods of use thereof
    Patent number: 10647731
    Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: May 12, 2020
    Assignee: Genentech, Inc.
    Inventors: Yu Jiang, Guosheng Wu, Po-Wai Yuen, Elisia Villemure, Jacob Schwarz, Cuong Ly, Benjamin Sellers, Matthew Volgraf
  • MIT BIOMARKERS AND METHODS USING THE SAME
    Publication number: 20200138944
    Abstract: Provided are therapies related to the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: October 9, 2019
    Publication date: May 7, 2020
    Applicant: Genentech, Inc.
    Inventors: Steffen Durinck, Bijay Jaiswal, Zora Modrusan, Somasekar Seshagiri, Eric Stawiski, Na Zhang
  • FGFR1 AGONISTS AND METHODS OF USE
    Publication number: 20200140557
    Abstract: The invention provides FGFR1 agonists, including agonistic anti-FGFR1 antibodies, and methods of using the same.
    Type: Application
    Filed: May 16, 2019
    Publication date: May 7, 2020
    Applicant: Genentech, Inc.
    Inventors: Junichiro Sonoda, Yan Wu
  • Silvestrol antibody-drug conjugates and methods of use
    Patent number: 10639378
    Abstract: The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: May 5, 2020
    Assignee: Genentech, Inc.
    Inventors: Thomas Pillow, Andrew G. Polson, Bing Zheng
  • Pyrrolobenzodiazepine antibody drug conjugates and methods of use
    Patent number: 10639373
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: May 5, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Anti-CD3 antibodies and methods of use
    Patent number: 10640572
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: May 5, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Teemu T. Junttila, Robert F. Kelley, Mary A. Mathieu
  • DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
    Publication number: 20200129519
    Abstract: The present invention provides diagnostic and therapeutic methods for cancer. The invention provides methods of determining whether a patient having a cancer is likely to respond to treatment comprising an inhibitor of H3K27 methylation, methods of predicting responsiveness of a patient having a cancer to treatment comprising one or more inhibitors of H3K27 methylation, methods of selecting a therapy for a patient having a cancer, and methods of treating cancer based on expression levels of biomarkers of the invention (e.g., the expression level of SIV1ARCA2 or the occupancy level of H3K27 at a SMARCA2 promoter).
    Type: Application
    Filed: June 8, 2017
    Publication date: April 30, 2020
    Applicants: Genentech, Inc., Genentech, Inc.
    Inventors: Robert L. YAUCH, Xiaofen YE, Thomas E. JANUARIO
  • BIOREACTORS WITH MULTIPLE OR ADJUSTABLE-POSITION AGITATOR DESIGNS
    Publication number: 20200131463
    Abstract: Described herein are bioreactor support structures configured to be used with containers having different designs, and methods for making and using such bioreactors. The support structures described herein may include two or more agitator motors and control systems or an adjustable-position agitator motor, a removable spacer and/or lid, multiple configurations for ports and probes, and multiple exhaust filter heating blankets. Also described herein are methods of manufacturing a multi-agitator motor or adjustable-position agitator motor bioreactor, as well as methods of modifying an existing support structure to be used with a container not originally designed to be used with the existing support structure, and methods for operating these bioreactors.
    Type: Application
    Filed: December 27, 2019
    Publication date: April 30, 2020
    Applicant: Genentech, Inc.
    Inventors: Ekta MAHAJAN, Kelsey DENT, Edward CHAN, Terry HUDSON, Neria DANIEL
  • METHODS OF TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20200131255
    Abstract: The invention provides methods of treating tauopathies with anti-Tau antibodies.
    Type: Application
    Filed: September 19, 2019
    Publication date: April 30, 2020
    Applicant: Genentech, Inc.
    Inventors: Geoffrey Kerchner, Edmond Teng
  • Peptidomimetic compounds and antibody-drug conjugates thereof
    Patent number: 10632210
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: April 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Ho Huat Lee, Moana Tercel, John A. Flygare, Janet Gunzner-Toste, Thomas H. Pillow, Brian Safina, Leanna Staben, Vishal Verma, BinQing Wei, Guiling Zhao
  • Pyrrolobenzodiazepine antibody drug conjugates and methods of use
    Patent number: 10632196
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: April 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Anti-tau antibodies and methods of use
    Patent number: 10633436
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: April 28, 2020
    Assignees: Genentech, Inc., AC Immune SA
    Inventors: Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
  • Expression and secretion system
    Patent number: 10633650
    Abstract: The invention provides an expression and secretion system, and methods of using the same, for the expression and secretion of one fusion protein in prokaryotic cells and a second fusion protein in eukaryotic cells. Also provided herein are nucleic acid molecules, vectors and host cells comprising such vectors and nucleic acid molecules.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: April 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Devin Tesar, Xiaocheng Chen, Mark Dennis, Isidro Hotzel
  • PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
    Publication number: 20200123166
    Abstract: Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 23, 2020
    Applicant: Genentech, Inc.
    Inventors: Marian C. BRYAN, Steven DO, Joy DROBNICK, Alberto GOBBI, Tamiko KATSUMOTO, James Richard KIEFER, Jr., Jun LIANG, Naomi S. RAJAPAKSA, Yongsheng CHEN, Liqiang FU, Kwong Wah LAI, Zhiguo LIU, John WAI, Fei WANG
  • Defect Detection in Lyophilized Drug Products with Convolutional Neural Networks
    Publication number: 20200126210
    Abstract: In one embodiment, a method includes receiving one or more querying images associated with a container of a pharmaceutical product, each of the one or more querying images being based on a particular angle of the container of the pharmaceutical product, calculating one or more confidence scores associated with one or more defect indications, respectively for the container of the pharmaceutical product, by processing the one or more querying images using a target machine-learning model, and determining a defect indication for the container of the pharmaceutical product from the one or more defect indications based on a comparison between the one or more confidence scores and one or more predefined threshold scores, respectively.
    Type: Application
    Filed: October 16, 2019
    Publication date: April 23, 2020
    Applicant: GENENTECH, INC.
    Inventor: Zheng Li